Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Saiqa Spensley"'
Autor:
Amit Bahl, William Wilson, Jessica Ball, Emily Renninson, Sidharth Dubey, Alicia Bravo, Emily Foulstone, Saiqa Spensley, Rebecca Bowen, Janine Mansi, Simon Waters, Pippa Riddle, Duncan Wheatley, Peter Stephens, Pavel Bezecny, Srinivasan Madhusudan, Mark Verrill, Jeremy Braybrooke, Charles Comins, Vivek Mohan, Abigail Gee, Hannah Kirk, Alison Markham, Heidi Evans, Eve Watson, Mark Callaway, Sylvia Pearson, Allan Hackshaw, Mark Churn
Publikováno v:
Breast, Vol 66, Iss , Pp 69-76 (2022)
Background: Paclitaxel is commonly used as first-line chemotherapy for HER2-negative metastatic breast cancer (MBC) patients. However, with response rates of 21.5–53.7% and significant risk of peripheral neuropathy, there is need for better chemoth
Externí odkaz:
https://doaj.org/article/82333b9202654f2ab93e6857aabae51e
Autor:
Ellen R. Copson, Jean E. Abraham, Jeremy P. Braybrooke, Stuart A. McIntosh, Caroline O. Michie, Carlo Palmieri, Rebecca Roylance, Saiqa Spensley
Publikováno v:
Cancer Research. 83:P3-05
PURPOSE: There is currently no standardised definition for patients at high risk of recurrence of HER2-negative early breast cancer (eBC, stages 1–3) after surgery. Recognising that the assessment of high risk is often multifactorial, the aim of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07b25603fc9c5e3bb2bf1d875cf4ad54
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-39
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-39
Autor:
Sidharth Dubey, William R. Wilson, Pippa Riddle, Peter Stephens, Alison Markham, Saiqa Spensley, Jessica Ball, Mark Churn, Pavel Bezecny, Mark Verrill, Rebecca Bowen, Sylvia Pearson, Duncan Wheatley, Alicia Bravo, Amit Bahl, Jeremy P Braybrooke, Srinivasan Madhusudan, S Waters, Emily J. Foulstone, Janine Mansi
Publikováno v:
Journal of Clinical Oncology. 39:1008-1008
1008 Background: Paclitaxel is commonly used as first line chemotherapy for HER2 negative MBC. However, with response rates of 21.5-53.7% and a significant risk of peripheral neuropathy there is a need for more effective and better tolerated chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7258cc3bb896d136bc2a2938e175115f
https://doi.org/10.1200/jco.2021.39.15_suppl.1008
https://doi.org/10.1200/jco.2021.39.15_suppl.1008
Publikováno v:
The Breast. 48:S68
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc3310c9ceca073ff805b2524e67b3ca
https://doi.org/10.1016/s0960-9776(19)30734-9
https://doi.org/10.1016/s0960-9776(19)30734-9
Autor:
Victoria Liversedge, Robert E. Coleman, Prabir Chakraborti, Saiqa Spensley, Richard Bell, Emma Rathbone, Geraldine A. Murden, H Marshall, R.K. Agrawal, Michelle Collinson, Frances Yuille, Rema Jyothirmayi, Janet E. Brown, David Cameron
Publikováno v:
Journal of Clinical Oncology. 31:2685-2691
Purpose In patients with early breast cancer, adjuvant zoledronic acid (zoledronate) may reduce recurrence and improve survival. However, zoledronate is associated with the occasional development of osteonecrosis of the jaw (ONJ). We report on the fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0605f02d3ffdee1fcaecd695b3a54e20
https://doi.org/10.1200/jco.2012.46.4792
https://doi.org/10.1200/jco.2012.46.4792
Publikováno v:
Clinical Oncology. 21:49-55
Aims Two recent meta-analyses have shown a survival advantage for the addition of concurrent chemotherapy to radiotherapy in the treatment of cervical cancer. However, there is insufficient information available on late toxicity and few data from UK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7f8d40d66bf2925c8119e2283b704ac
https://doi.org/10.1016/j.clon.2008.10.014
https://doi.org/10.1016/j.clon.2008.10.014